Johnson & Johnson’s single-dose COVID-19 vaccine gets EUA in India

The statement added that it was an important milestone that has paved the way to bring the company’s single-dose COVID-19 vaccine to the people of India and for the rest of the world with a collaboration with Biological E Limited.

On Saturday, Mansukh Mandaviya, Union Health Minister, had said that Johnson&Johnson’s single-dose COVID-19 vaccine had been given approval for emergency use in India. He said that now India has 5 EUA vaccines which would further boost the nation’s collective fight against COVID-19.

The Phase 3 Ensemble Clinical trial demonstrated Johnson& Johnson’s single-shot vaccines to be 85 per cent effective in the prevention of severe diseases across every region studied and the vaccine also showed protection against the hospitalisation and deaths related to COVID-19, which began 28 days post-vaccination, all this was the base of the EUA submission.

The statement added that it was an important milestone that has paved the way to bring the company’s single-dose COVID-19 vaccine to the people of India and for the rest of the world with a collaboration with Biological E Limited.

The statement further said that they were looking forward to concluding their discussions with the government of India in order to accelerate the availability of their COVID-19 vaccine to end the pandemic.

Subscribe to our newsletter
Subscribe to our newsletter
Sign up here to get the latest news delivered directly to your inbox.
You can unsubscribe at any time